VYNE Therapeutics Inc. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
VYNE Therapeutics is executing a reverse merger with Yarrow Bioscience, expected to close ~July 24, 2026, with combined entity trading as YARW on NASDAQ. Yarrow in-licensed exclusive rights to YB-101 (anti-TSHR antibody) from GenSci in December 2025 for Graves' Disease and Thyroid Eye Disease treatment outside greater China. $200M raised to date ($100M from pre-closing financing); Phase 2a/2b GD trial initiated Q2 2026 with Phase 2a readout expected H2 2027. Post-closing, Yarrow shareholders will own ~97% of combined company; VYNE shareholders ~3%. Cash runway expected into 2028.
Why this rating
Transformational for $32M VYNE: reverse merger brings $200M in capital, clinical-stage asset, and experienced biotech leadership. However, VYNE shareholders heavily diluted to 3% ownership. High clinical execution risk on early-stage program.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.